BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dang H, Sun J, Wang G, Renner G, Layfield L, Hilli J. Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. World J Clin Cases 2020; 8(18): 4100-4108 [PMID: 33024767 DOI: 10.12998/wjcc.v8.i18.4100]
URL: https://www.wjgnet.com/2307-8960/full/v8/i18/4100.htm
Number Citing Articles
1
Barbara Ma, Niroshana Anandasabapathy. Immune Checkpoint Blockade and Skin Toxicity PathogenesisJournal of Investigative Dermatology 2022; 142(3): 951 doi: 10.1016/j.jid.2021.06.040
2
Naoki Kawakami, Hiroaki Saito, Susumu Takahashi, Shinpei Kajie, Rina Kato, Kazuhiro Shimaya, Yoko Wakai, Kazuhito Saito, Mai Sakashita. Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic reviewSeminars in Oncology 2022; 49(6): 439 doi: 10.1053/j.seminoncol.2023.01.003
3
Malek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, Antonio Pizuorno Machado, Sidra Naz, Nitish Mittal, Christine Catinis, Krishnavathana Varatharajalu, Carolina Colli Cruz, Eric Lu, Deanna Wu, Julie R Brahmer, Franck Carbonnel, Stephen B Hanauer, Bret Lashner, Bryan Schneider, John A Thompson, Michel Obeid, David P Farris, Yinghong Wang. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse eventsJournal for ImmunoTherapy of Cancer 2024; 12(11): e009742 doi: 10.1136/jitc-2024-009742
4
Siyuan Hao, Yixin Jin, Yue Yu, Jiantao Wang, Jing Zou, Yan Wang. Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositisSupportive Care in Cancer 2023; 31(4) doi: 10.1007/s00520-023-07686-7
5
PembrolizumabReactions Weekly 2020; 1829(1): 316 doi: 10.1007/s40278-020-85906-1